CymaBay Therapeutics is a biopharmaceutical company focused on developing and providing access to therapies for patients with liver and other diseases. Co.'s pipeline includes two clinical stage product candidates: seladelpar (MBX-8025), which is a selective agonist for the peroxisome proliferator-activated receptor delta and has the potential to treat certain diseases of the liver and disorders of lipid metabolism; and MBX-2982, which targets G protein-coupled receptor 119, a receptor that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion. Co. has one preclinical stage product candidate, CB-001, which targets G protein-coupled receptor 120. The CBAY stock yearly return is shown above.
The yearly return on the CBAY stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2015 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the CBAY annual return calculation with any dividends reinvested as applicable (on ex-dates).
|